194 related articles for article (PubMed ID: 27453436)
21. MicroRNA 345, a methylation-sensitive microRNA is involved in cell proliferation and invasion in human colorectal cancer.
Tang JT; Wang JL; Du W; Hong J; Zhao SL; Wang YC; Xiong H; Chen HM; Fang JY
Carcinogenesis; 2011 Aug; 32(8):1207-15. PubMed ID: 21665895
[TBL] [Abstract][Full Text] [Related]
22. DNA Hypermethylation of SHISA3 in Colorectal Cancer: An Independent Predictor of Poor Prognosis.
Tsai MH; Chen WC; Yu SL; Chen CC; Jao TM; Huang CY; Tzeng ST; Yen SJ; Yang YC
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1481-9. PubMed ID: 25968618
[TBL] [Abstract][Full Text] [Related]
23. Methylation associated transcriptional repression of ELOVL5 in novel colorectal cancer cell lines.
Boot A; Oosting J; van Eendenburg JDH; Kuppen PJK; Morreau H; van Wezel T
PLoS One; 2017; 12(9):e0184900. PubMed ID: 28931069
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas.
Oster B; Thorsen K; Lamy P; Wojdacz TK; Hansen LL; Birkenkamp-Demtröder K; Sørensen KD; Laurberg S; Orntoft TF; Andersen CL
Int J Cancer; 2011 Dec; 129(12):2855-66. PubMed ID: 21400501
[TBL] [Abstract][Full Text] [Related]
25. Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer.
Philipp AB; Nagel D; Stieber P; Lamerz R; Thalhammer I; Herbst A; Kolligs FT
BMC Cancer; 2014 Apr; 14():245. PubMed ID: 24708595
[TBL] [Abstract][Full Text] [Related]
26. PBX3 hypermethylation in peripheral blood leukocytes predicts better prognosis in colorectal cancer: A propensity score analysis.
Sun H; Huang H; Li D; Zhang L; Zhang Y; Xu J; Liu Y; Liu Y; Zhao Y
Cancer Med; 2019 Jul; 8(8):4001-4011. PubMed ID: 31140752
[TBL] [Abstract][Full Text] [Related]
27. Clinical and prognosis value of the CIMP status combined with MLH1 or p16
Saadallah-Kallel A; Abdelmaksoud-Dammak R; Triki M; Charfi S; Khabir A; Sallemi-Boudawara T; Mokdad-Gargouri R
Med Oncol; 2017 Aug; 34(8):147. PubMed ID: 28730335
[TBL] [Abstract][Full Text] [Related]
28. Association of ZNF331 and WIF1 methylation in peripheral blood leukocytes with the risk and prognosis of gastric cancer.
Nie C; Han X; Wei R; Leonteva A; Hong J; Du X; Wang J; Zhu L; Zhao Y; Xue Y; Zhou H; Tian W
BMC Cancer; 2021 May; 21(1):551. PubMed ID: 33992091
[TBL] [Abstract][Full Text] [Related]
29. Aberrant TET1 Methylation Closely Associated with CpG Island Methylator Phenotype in Colorectal Cancer.
Ichimura N; Shinjo K; An B; Shimizu Y; Yamao K; Ohka F; Katsushima K; Hatanaka A; Tojo M; Yamamoto E; Suzuki H; Ueda M; Kondo Y
Cancer Prev Res (Phila); 2015 Aug; 8(8):702-11. PubMed ID: 26063725
[TBL] [Abstract][Full Text] [Related]
30. DNA methylation markers in colorectal cancer.
Kim MS; Lee J; Sidransky D
Cancer Metastasis Rev; 2010 Mar; 29(1):181-206. PubMed ID: 20135198
[TBL] [Abstract][Full Text] [Related]
31. A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility.
Onwuka JU; Li D; Liu Y; Huang H; Xu J; Liu Y; Zhang Y; Zhao Y
BMC Cancer; 2020 Jul; 20(1):692. PubMed ID: 32711505
[TBL] [Abstract][Full Text] [Related]
32. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic signatures of familial cancer are characteristic of tumor type and family category.
Joensuu EI; Abdel-Rahman WM; Ollikainen M; Ruosaari S; Knuutila S; Peltomäki P
Cancer Res; 2008 Jun; 68(12):4597-605. PubMed ID: 18559504
[TBL] [Abstract][Full Text] [Related]
34. Screening for genomic fragments that are methylated specifically in colorectal carcinoma with a methylated MLH1 promoter.
Koinuma K; Kaneda R; Toyota M; Yamashita Y; Takada S; Choi YL; Wada T; Okada M; Konishi F; Nagai H; Mano H
Carcinogenesis; 2005 Dec; 26(12):2078-85. PubMed ID: 16033773
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic and prognostic role of cell-free DNA testing for colorectal cancer patients.
Bedin C; Enzo MV; Del Bianco P; Pucciarelli S; Nitti D; Agostini M
Int J Cancer; 2017 Apr; 140(8):1888-1898. PubMed ID: 27943272
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
[TBL] [Abstract][Full Text] [Related]
37. The variation trends of SFRP2 methylation of tissue, feces, and blood detection in colorectal cancer development.
Sui C; Ma J; Chen Q; Yang Y
Eur J Cancer Prev; 2016 Jul; 25(4):288-98. PubMed ID: 26258809
[TBL] [Abstract][Full Text] [Related]
38. Bacterially-Associated Transcriptional Remodelling in a Distinct Genomic Subtype of Colorectal Cancer Provides a Plausible Molecular Basis for Disease Development.
Lennard KS; Goosen RW; Blackburn JM
PLoS One; 2016; 11(11):e0166282. PubMed ID: 27846243
[TBL] [Abstract][Full Text] [Related]
39. Hypermethylation-Associated Silencing of miR-125a and miR-125b: A Potential Marker in Colorectal Cancer.
Chen H; Xu Z
Dis Markers; 2015; 2015():345080. PubMed ID: 26693202
[TBL] [Abstract][Full Text] [Related]
40. Distinct features between MLH1-methylated and unmethylated colorectal carcinomas with the CpG island methylator phenotype: implications in the serrated neoplasia pathway.
Kim JH; Bae JM; Cho NY; Kang GH
Oncotarget; 2016 Mar; 7(12):14095-111. PubMed ID: 26883113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
